- Home
- KPRX vs VERB Comparison
KPRX vs VERB Comparison
Compare KPRX & VERB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- VERB
- Stock Information
- Founded
- KPRX 1998
- VERB 2014
- Country
- KPRX United States
- VERB United States
- Employees
- KPRX N/A
- VERB N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- VERB Other Consumer Services
- Sector
- KPRX Health Care
- VERB Consumer Discretionary
- Exchange
- KPRX Nasdaq
- VERB Nasdaq
- Market Cap
- KPRX 8.6M
- VERB 9.6M
- IPO Year
- KPRX N/A
- VERB N/A
- Fundamental
- Price
- KPRX $2.99
- VERB $8.72
- Analyst Decision
- KPRX Strong Buy
- VERB Strong Buy
- Analyst Count
- KPRX 1
- VERB 1
- Target Price
- KPRX $10.00
- VERB $62.00
- AVG Volume (30 Days)
- KPRX 62.4K
- VERB 27.3K
- Earning Date
- KPRX 08-08-2025
- VERB 08-13-2025
- Dividend Yield
- KPRX N/A
- VERB N/A
- EPS Growth
- KPRX N/A
- VERB N/A
- EPS
- KPRX N/A
- VERB N/A
- Revenue
- KPRX $20,000.00
- VERB $2,193,000.00
- Revenue This Year
- KPRX N/A
- VERB $526.82
- Revenue Next Year
- KPRX N/A
- VERB $45.45
- P/E Ratio
- KPRX N/A
- VERB N/A
- Revenue Growth
- KPRX N/A
- VERB 3125.00
- 52 Week Low
- KPRX $2.51
- VERB $3.81
- 52 Week High
- KPRX $4.80
- VERB $20.60
- Technical
- Relative Strength Index (RSI)
- KPRX 47.28
- VERB 56.90
- Support Level
- KPRX $2.96
- VERB $8.43
- Resistance Level
- KPRX $3.29
- VERB $9.47
- Average True Range (ATR)
- KPRX 0.15
- VERB 0.61
- MACD
- KPRX 0.01
- VERB -0.02
- Stochastic Oscillator
- KPRX 38.78
- VERB 65.57
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About VERB Verb Technology Company Inc.
Verb Technology Co Inc leader in interactive video-based sales applications, transforms how businesses attract and engage customers. VERB's Software-as-a-Service platform, based on its proprietary interactive video technology, comprises a suite of easy-to-use, subscription-based sales enablement software products. The segments of the company are MARKET.live and Go Fund Yourself, and it derives maximum revenue from MARKET.live segment.